Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
AMRN

AMRN - Amarin Corp PLC Stock Price, Fair Value and News

1.16USD-0.02 (-1.69%)Delayed as of 23 Feb 2024, 09:57 am ET
Watchlist

Market Summary

USD1.16-0.02
Delayedas of 23 Feb 2024, 09:57 am
-1.69%

AMRN Alerts

  • 1 major insider buys recently.

AMRN Stock Price

View Fullscreen

AMRN RSI Chart

AMRN Valuation

Market Cap

482.1M

Price/Earnings (Trailing)

-9.19

Price/Sales (Trailing)

1.5

EV/EBITDA

-3.64

Price/Free Cashflow

53.11

AMRN Price/Sales (Trailing)

AMRN Profitability

EBT Margin

-17.99%

Return on Equity

-9.49%

Return on Assets

-6.25%

Free Cashflow Yield

1.88%

AMRN Fundamentals

AMRN Revenue

Revenue (TTM)

322.4M

Rev. Growth (Yr)

-26.5%

Rev. Growth (Qtr)

-17.6%

AMRN Earnings

Earnings (TTM)

-52.5M

Earnings Growth (Yr)

-275.7%

Earnings Growth (Qtr)

-9.97%

Breaking Down AMRN Revenue

52 Week Range

1.19
(Low)(High)

Last 7 days

-0.8%

Last 30 days

2.5%

Last 90 days

47.6%

How does AMRN drawdown profile look like?

AMRN Financial Health

Current Ratio

2.69

Debt/Equity

0.02

Debt/Cashflow

1.02

AMRN Investor Care

Shares Dilution (1Y)

2.15%

Diluted EPS (TTM)

-0.12

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023360.5M346.3M322.4M0
2022535.6M475.6M423.4M369.2M
2021601.2M620.4M605.9M583.2M
2020511.5M546.0M590.1M614.1M
2019258.6M306.7M363.8M429.8M
2018190.4M197.8M205.8M229.2M
2017139.2M151.3M165.9M181.1M
201691.4M106.8M118.0M130.1M
201559.2M64.3M71.6M81.8M
201435.0M42.1M47.8M54.2M
201300026.4M

Tracking the Latest Insider Buys and Sells of Amarin Corp PLC

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jan 31, 2024
berg aaron
acquired
-
-
79,500
evp, president us
Jan 31, 2024
reilly thomas charles
sold (taxes)
-30,444
1.24
-24,552
evp and cfo
Jan 31, 2024
berg aaron
sold (taxes)
-50,619
1.24
-40,822
evp, president us
Jan 31, 2024
ketchum steven b
sold (taxes)
-51,071
1.24
-41,187
chief scientific officer
Jan 31, 2024
reilly thomas charles
acquired
-
-
44,933
evp and cfo
Jan 31, 2024
ketchum steven b
acquired
-
-
79,500
chief scientific officer
Jan 22, 2024
holt patrick
bought
15,724
1.09
14,426
president and ceo
Jan 10, 2024
berg aaron
acquired
-
-
51,500
evp, president us
Jan 10, 2024
berg aaron
sold (taxes)
-27,367
0.97
-28,214
evp, president us
Jan 10, 2024
reilly thomas charles
acquired
-
-
51,500
evp and cfo

1–10 of 50

Which funds bought or sold AMRN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
added
1,761
698,000
740,000
0.06%
Feb 16, 2024
HARBOUR INVESTMENTS, INC.
reduced
-4.84
-190
1,710
-%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
unchanged
-
-4,000
77,000
-%
Feb 15, 2024
Sunbelt Securities, Inc.
unchanged
-
-389
6,769
-%
Feb 15, 2024
JANE STREET GROUP, LLC
new
-
133,810
133,810
-%
Feb 15, 2024
GTS SECURITIES LLC
added
1.29
-1,703
38,708
-%
Feb 15, 2024
BARCLAYS PLC
unchanged
-
-1,000
8,000
-%
Feb 15, 2024
Arkos Global Advisors
unchanged
-
-
9,000
-%
Feb 15, 2024
Farther Finance Advisors, LLC
new
-
9,266
9,266
-%
Feb 14, 2024
MILLENNIUM MANAGEMENT LLC
added
95.16
1,011,840
2,208,580
-%

1–10 of 44

Are Funds Buying or Selling AMRN?

Are funds buying AMRN calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AMRN
No. of Funds

Unveiling Amarin Corp PLC's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Dec 08, 2023
morgan stanley
1.6%
6,427,739
SC 13G/A
Dec 05, 2023
sarissa capital management lp
8.20%
33,470,000
SC 13D/A
Feb 10, 2023
sarissa capital management lp
-
0
SC 13D/A
Dec 12, 2022
baker bros. advisors lp
0.0%
0
SC 13G/A
Oct 11, 2022
sarissa capital management lp
5.95%
2.4e+07
SC 13D/A
Feb 14, 2020
baker bros. advisors lp
9.6%
34,496,685
SC 13G/A

Recent SEC filings of Amarin Corp PLC

View All Filings
Date Filed Form Type Document
Feb 12, 2024
PRE 14A
PRE 14A
Feb 09, 2024
4
Insider Trading
Feb 09, 2024
4
Insider Trading
Feb 09, 2024
4
Insider Trading
Feb 02, 2024
4
Insider Trading
Feb 02, 2024
4
Insider Trading
Feb 02, 2024
4
Insider Trading
Jan 26, 2024
8-K
Current Report
Jan 24, 2024
4
Insider Trading
Jan 12, 2024
4
Insider Trading

What is the Fair Value of AMRN?

Loading...
Disclaimer: Conduct thorough research and seek guidance from a certified financial advisor prior to finalizing any investment choices.

Peers (Alternatives to Amarin Corp PLC)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
386.5B
93.0B
-3.60% -2.76%
10.99
4.15
6.46% 95.94%
156.0B
46.5B
-3.76% -37.06%
-112.32
3.35
42.59% -114.62%
152.8B
28.2B
-7.44% 18.02%
22.75
5.42
7.09% 2.52%
90.7B
27.4B
-17.13% -16.65%
15.44
3.31
0.94% 76.21%
14.6B
15.8B
15.02% 26.90%
-26.19
0.92
6.17% 77.01%
MID-CAP
4.8B
1.7B
14.11% 18.79%
13.58
2.9
49.61% 324.78%
4.3B
4.7B
-2.94% -9.06%
-1.1K
0.93
5.74% 96.18%
3.1B
8.8B
-0.23% 18.85%
-5.25
0.35
7.79% -163.11%
2.5B
601.3M
-0.28% 70.16%
18.38
4.14
24.02% 75.17%
SMALL-CAP
1.3B
700.5M
2.67% -
-0.93
1.9
16.26% -147.49%
23.8M
70.0M
-0.88% -54.80%
0.35
0.34
-19.54% 888.31%
22.4M
84.1M
58.23% -28.98%
-1.05
0.22
2882.68% -145.15%
16.8M
111.1M
-6.33% -18.68%
-1.05
0.15
-10.43% 84.90%
2.4M
20.0M
-35.83% -91.10%
-0.17
0.12
137.71% 66.04%

Amarin Corp PLC News

Latest updates
InvestorsObserver08 Feb 202411:58 am
Zacks Investment Research11 Jan 202408:00 am
Yahoo Finance2 months ago
The Motley Fool7 months ago

Amarin Corp PLC Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue-17.6%66,056,00080,167,00085,975,00090,245,00089,878,00094,440,00094,630,000144,491,000142,038,000154,488,000142,170,000167,251,000156,499,000135,317,000154,993,000143,277,000112,408,000100,792,00073,278,00077,330,00055,323,000
Gross Profit-30.1%29,822,00042,668,00047,927,00063,604,00062,859,00043,630,00072,391,000113,856,000111,827,000122,333,000113,844,000132,482,500123,428,000106,520,000120,186,000112,612,00086,964,00078,022,00056,138,00059,821,00041,782,000
Operating Expenses-23.0%51,273,00066,627,00065,268,00073,190,00068,003,000106,462,000100,698,00097,723,000124,900,000113,560,000115,175,000125,324,500130,368,000102,364,000144,215,000107,122,00091,482,00080,536,00078,875,00091,592,50064,032,000
  S&GA Expenses-10.8%45,457,00050,953,00059,587,00068,131,00058,745,00086,893,00090,647,00092,368,000102,965,000107,203,000105,798,000116,816,000120,164,00092,395,000133,937,00096,025,00082,559,00073,406,00071,633,00079,685,50049,960,000
  R&D Expenses-9.5%5,105,0005,642,0005,681,0005,239,0005,765,0009,356,00010,051,0005,753,0007,820,0006,357,0009,377,0008,508,50010,204,0009,969,00010,278,00011,097,0008,923,0007,130,0007,242,00011,907,00014,072,000
EBITDA Margin-44.7%-0.18-0.12-0.25-0.28-0.19-0.19-0.030.020.010.020.01-0.02-0.02-0.04-0.04-0.04-0.18-0.23-0.41-0.47-0.38
Interest Expenses------------723,000689,000318,000875,0003,049,000-11,405,0007,273,0007,709,000-7,158,0005,779,000
Income Taxes241.1%501,000-355,0001,964,000-7,629,0001,257,0005,157,0003,213,0001,695,000184,0001,059,000624,0002,674,000430,000--2,359,00077,00016,000---729,00020,000
Earnings Before Taxes-5.0%-18,810,000-17,915,000-14,496,000-6,773,000-3,883,000-64,799,000-28,350,00016,393,000-12,967,0008,867,000-1,002,0007,600,000-6,358,0004,415,000-22,912,0007,232,000-3,462,000-1,820,000-24,431,000-33,573,000-24,471,000
EBT Margin-44.6%-0.18-0.12-0.25-0.28-0.19-0.19-0.030.020.000.010.01-0.03-0.03-0.03-0.04-0.05-0.17-0.27-0.45-0.51-0.45
Net Income-10.0%-19,311,000-17,560,000-16,460,000856,000-5,140,000-69,956,000-31,563,00014,698,000-13,151,0007,808,000-1,626,0004,926,000-6,788,0004,415,000-20,553,0007,068,000-3,462,000-1,820,000-24,431,000-33,670,000-24,471,000
Net Income Margin-47.1%-0.16-0.11-0.25-0.29-0.22-0.21-0.040.010.000.010.00-0.03-0.03-0.02-0.04-0.05-0.17-0.28-0.45-0.51-0.51
Free Cashflow1.7%7,329,0007,204,000-7,008,0001,552,000-18,213,000-64,584,000-98,847,000-28,240,000-4,540,000-15,053,000-18,704,000-38,323,00010,852,0001,587,0003,886,000-9,300,00020,437,00015,904,000-38,094,000-32,308,000-28,157,000
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-2.4%8398608608869089739741,0681,0361,045990966960915926882867390372386210
  Current Assets1.6%718706684689687719773879963996931879889828817855848372355378202
    Cash Equivalents16.2%27123319121824022821921922332729118720721432964567322221124982.00
  Inventory12.1%25422722622922822626823530927223118914912592.0077.0055.0046.0058.0058.0044.00
  Net PPE-17.9%0.000.000.001.001.001.001.001.002.002.002.002.002.002.002.002.002.001.000.000.000.00
Liabilities-1.7%286291275291320393333401393400356339353312340274271241231233263
  Current Liabilities-1.6%267271244259287362301371365370326307326283310242230185162157152
  Long Term Debt-----------------9.0023.0035.0046.0054.00
    LT Debt, Current-------------9.0022.0037.0050.0051.0045.0039.0034.0030.00
    LT Debt, Non Current-----------------9.0023.0035.0046.0054.00
Shareholder's Equity-2.8%5535695855955885806416676426456356286076035866085961491411521,057
  Retained Earnings-1.2%-1,580-1,561-1,543-1,527-1,528-1,522-1,453-1,421-1,436-1,422-1,430-1,429-1,434-1,427-1,431-1,411-1,418-1,414-1,412-1,388-1,354
  Additional Paid-In Capital0.2%1,8951,8921,8901,8851,8791,8701,8611,8551,8451,8351,8311,8181,7991,7871,7751,7641,7461,3121,3011,2831,057
Shares Outstanding0.1%409408407404400398398397396396395382390385361343351330329297296
Float------721---1,710---2,645---6,372---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations1.7%7,3297,204-7,0081,552-18,213-64,584-98,847-28,240-4,540-15,053-18,704-38,32310,8531,5874,137-8,93621,75015,909-38,089-32,303-28,157
  Share Based Compensation96.6%3,6081,8355,5566,6124,8778,6466,07810,10210,4322,47913,92511,50811,58312,13110,5918,1887,9637,8836,8834,7746,651
Cashflow From Investing-10.4%30,76734,320-19,610-27,81930,86873,19099,04925,016-99,49150,649127,92923,686-4,359-102,468-293,822-364-1,313---5.00-
Cashflow From Financing-561.7%-27760.0036438.00-156244-505-196-110426-5,193-5,606-13,292-14,154-25,855-19,316433,400-4,425-47.00200,5437,845

AMRN Income Statement

2023-09-30
Condensed Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Total revenue, net$ 66,056$ 89,878$ 232,198$ 278,948
Less: Cost of goods sold23,56023,94172,55381,990
Less: Cost of goods sold - restructuring inventory12,6743,07839,22818,078
Gross margin29,82262,859120,417178,880
Operating expenses:    
Selling, general and administrative45,45758,745155,997236,285
Research and development5,1055,76516,42825,172
Restructuring expenses7113,49310,74313,706
Total operating expenses51,27368,003183,168275,163
Operating loss(21,451)(5,144)(62,751)(96,283)
Interest income, net3,2167508,4381,241
Other (expense) income, net(575)5113,092(1,990)
Loss from operations before taxes(18,810)(3,883)(51,221)(97,032)
Provision for income taxes(501)(1,257)(2,110)(9,627)
Net loss$ (19,311)$ (5,140)$ (53,331)$ (106,659)
Loss per share:    
Basic[1]$ (0.05)$ (0.01)$ (0.13)$ (0.27)
Diluted[1]$ (0.05)$ (0.01)$ (0.13)$ (0.27)
Weighted average shares:    
Basic408,417404,614407,489399,944
Diluted408,417404,614407,489399,944
Product Revenue, Net    
Total revenue, net$ 64,903$ 89,222$ 214,744$ 277,004
Licensing and Royalty Revenue    
Total revenue, net$ 1,153$ 656$ 17,454$ 1,944
[1]Excluding the licensing revenue change in estimateand Medicaid change in estimate, both discussed in Note 7 – Revenue Recognition, net loss per share basic and diluted for the three and nine months ended September 30, 2023 would have been $(0.06) and $(0.19), respectively.

AMRN Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current Assets:  
Cash and cash equivalents$ 270,814$ 217,666
Restricted cash524523
Short-term investments49,84891,695
Accounts receivable, net122,400130,990
Inventory254,461228,732
Prepaid and other current assets19,46419,492
Total current assets717,511689,098
Property, plant and equipment, net147874
Long-term investments 1,275
Long-term inventory91,792163,620
Operating lease right-of-use asset8,5109,074
Other long-term assets1,395458
Intangible asset, net19,67621,780
TOTAL ASSETS839,031886,179
Current Liabilities:  
Accounts payable53,36264,602
Accrued expenses and other current liabilities211,304192,678
Current deferred revenue2,0252,199
Total current liabilities266,691259,479
Long-Term Liabilities:  
Long-term deferred revenue2,94913,147
Long-term operating lease liability8,97010,015
Other long-term liabilities7,2738,205
Total liabilities285,883290,846
Commitments and contingencies (Note 5)
Stockholders’ Equity:  
Common stock, GBP 0.50 par, unlimited authorized; 417,744,958 shares issued, 408,551,020 shares outstanding as of September 30,2023; 412,333,087 shares issued, 404,346,256 shares outstanding as of December 31, 2022302,318299,002
Additional paid-in capital1,895,1551,885,352
Treasury stock; 9,193,938 shares as of September 30, 2023; 7,986,831 shares as of December 31, 2022(63,743)(61,770)
Accumulated deficit(1,580,582)(1,527,251)
Total stockholders’ equity553,148595,333
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY$ 839,031$ 886,179
AMRN
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
 CEO
 WEBSITEwww.amarincorp.com
 EMPLOYEES365

Amarin Corp PLC Frequently Asked Questions


What is the ticker symbol for Amarin Corp PLC? What does AMRN stand for in stocks?

AMRN is the stock ticker symbol of Amarin Corp PLC. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Amarin Corp PLC (AMRN)?

As of Thu Feb 22 2024, market cap of Amarin Corp PLC is 482.09 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AMRN stock?

You can check AMRN's fair value in chart for subscribers.

What is the fair value of AMRN stock?

You can check AMRN's fair value in chart for subscribers. The fair value of Amarin Corp PLC is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Amarin Corp PLC is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AMRN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Amarin Corp PLC a good stock to buy?

The fair value guage provides a quick view whether AMRN is over valued or under valued. Whether Amarin Corp PLC is cheap or expensive depends on the assumptions which impact Amarin Corp PLC's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AMRN.

What is Amarin Corp PLC's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 22 2024, AMRN's PE ratio (Price to Earnings) is -9.19 and Price to Sales (PS) ratio is 1.5. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AMRN PE ratio will change depending on the future growth rate expectations of investors.